RxDoctor Payments Data

Nathan Ostler

Family · Mesa, AZNPI 1023412301

Payments from drug & device makers

$1,120in general payments, 2019–2025

Across 49 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$421
  • UCB, Inc.$109
  • Novo Nordisk$89
  • Lilly USA, LLC$66
  • Novartis$61
  • Boehringer Ingelheim$42
  • plus $331 from 16 others

What the payments were for

  • Food & beverage$1,120100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,120 in reported general payments places this provider in the 70th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$72,826
Medicare patients
97
Services billed
1,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide13$21,982
TrulicityDulaglutide14$11,676
Levothyroxine Sodium68$1,066
Gabapentin35$896
Rosuvastatin Calcium32$669
Losartan Potassium43$645
Liothyronine Sodium12$559
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$445
Duloxetine Hcl16$439
Cefdinir20$418
Tamsulosin Hcl18$407
Atorvastatin Calcium41$389
Pantoprazole Sodium26$302
Lisinopril30$294
Montelukast Sodium12$262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$89$21,98213 claims
Lilly USA, LLCTrulicity$66$11,67614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,119 family providers in Arizona.

Other family in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →